George Theodorakopoulos

Mr. George Theodorakopoulos

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2025 in International Wound Journal
Verified
Journal Article
Open access
George TheodorakopoulosGeorge Theodorakopoulos
George Theodorakopoulos
DADavid G. Armstrong
David G. Armstrong
Biofilms are a key driver of chronicity and treatment failure in diabetic foot ulcers (DFUs), yet clinical evidence quantifying their impact and management remains fragmented. This systematic narrative review synthesised recent evidence (2015–2025) on the prevalence, diagnostics, and management of biofilm in DFUs. A Systematic Review of the Literature (SRL) was conducted following PRISMA 2020 guidelines across PubMed/MEDLINE, Scopus, Cochrane Library and ScienceDirect. Eligible studies included adults with DFUs reporting biofilm/bioburden metrics or interventions aimed at biofilm disruption. Risk of bias was assessed using RoB 2 for randomised trials and ROBINS‐I for non‐randomised studies. Data were narratively synthesised by evidence tier (Tier 1 = clinical; Tier 2 = preclinical/mechanistic). Of 600 records screened, 25 studies met inclusion criteria (Tier 1 n = 9; Tier 2 n = 5; reviews n = 11). Over half of bacterial isolates in DFUs were biofilm producers, with multidrug resistance exceeding 90% in several cohorts. Fungi were detected in 31% of ulcers by qPCR but only 9% by culture. Tier 1 clinical evidence supports standard care components—debridement, antiseptics, and negative‐pressure wound therapy—for improved healing, though direct antibiofilm outcomes remain limited. Emerging strategies (enzymatic agents, peptides, cold plasma, smart dressings) show promise in vitro but lack clinical translation. Evidence for direct antibiofilm efficacy in DFUs remains scarce. Current data justify maintaining guideline‐based care while prioritising trials that integrate validated biofilm endpoints, standardised microbiological methods, and antifungal components. Distinguishing established from experimental approaches is essential to advancing safe, evidence‐based biofilm management in DFUs.

1 November 2025 in Diabetology
Verified
Journal Article
Open access
PDF file
George TheodorakopoulosGeorge Theodorakopoulos
George Theodorakopoulos
David ArmstrongDavid Armstrong
David Armstrong
Background: Diabetic foot ulcers (DFUs) carry high risks of infection, amputation, and mortality. We systematically reviewed randomized controlled trials (RCTs) of negative-pressure wound therapy (NPWT), including single-use systems, for clinically uninfected DFUs (with sensitivity analyses for mixed/infected cohorts). Methods: We searched PubMed and Scopus (1 January 2004–30 June 2024). Dual reviewers performed screening and extraction; risk of bias was assessed with Cochrane Risk of Bias 2 (RoB 2) and certainty of evidence with GRADE. When ≥2 trials reported comparable outcomes, we used random-effects meta-analysis. The DiaFu cohort reported in two publications was counted once across analyses. Results: Eleven RCT publications (n = 1699; 10 unique cohorts) met criteria; eight trials (n = 1456) informed the primary endpoint. Trials largely excluded severe ischemia; findings therefore apply mainly to neuropathic or mixed-etiology DFUs with adequate perfusion. NPWT increased complete healing at 12–16 weeks (risk ratio [RR] 1.46, 95% CI 1.21–1.76; I2 = 48%) and shortened time to healing (mean difference –18 days, 95% CI −28 to −8). Effects were similar for conventional and single-use NPWT. Outcomes did not vary systematically within commonly used pressure ranges (approximately −80 to −125 mmHg). Only two RCTs reported direct cost data (exploratory). Moderate heterogeneity (Higgins’ I2 48–68%) reflected variation in ulcer severity, device type/settings, dressing-change frequency, and off-loading protocols. Conclusions: NPWT probably improves short-term healing of clinically uninfected DFUs compared with standard care and may reduce minor amputations, without increasing adverse events. Certainty is moderate for healing and low for most secondary outcomes. Benefits appear consistent across device classes and may support earlier discharge and community-based care. Evidence gaps include ischemia-dominated ulcers, long-term outcomes (recurrence and limb preservation), adherence mechanisms, and contemporary cost-effectiveness.

17 November 2025 in International Wound Journal
Verified
Journal Article
Open access
George TheodorakopoulosGeorge Theodorakopoulos
George Theodorakopoulos
DADavid G. Armstrong
David G. Armstrong
Diabetic foot ulcers (DFUs) are a major cause of infection, hospitalisation, and amputation. Collagen‐based dressings—especially collagen combined with oxidised regenerated cellulose (ORC)—are proposed to improve healing by modulating matrix metalloproteinases (MMPs), stabilising the extracellular matrix (ECM), and tempering inflammation; some formulations also include antimicrobial or bioactive adjuncts. We conducted a systematic review of randomised controlled trials (RCTs) following Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidance. Adults with DFUs were eligible. Interventions included collagen‐alone or collagen‐combination dressings (e.g., collagen–oxidised regenerated cellulose [collagen–ORC]/silver, collagen–chitosan) versus standard of care (SOC) or alternative dressings. To ensure comparable outcomes, the quantitative synthesis was pre‐specified and restricted to complete wound closure (yes/no, intention‐to‐treat [ITT]) from collagen‐combination RCTs with aligned constructs; other outcomes were synthesised narratively. Meta‐analyses were performed in Microsoft Excel using Mantel–Haenszel methods for risk ratios (RR) with a fixed‐effect primary model and DerSimonian–Laird random‐effects sensitivity analysis; heterogeneity was summarised with Cochran's Q, between‐study variance ( τ 2 ), and Higgins' I 2 statistic ( I 2 ), and a 95% prediction interval was reported for random‐effects. (Protocol not registered). Six studies (five randomized controlled trials and one single‐blinded non‐randomized comparative study; total n = 314) met inclusion. In a focused meta‐analysis of the two collagen‐combination RCTs, treatment was associated with a higher probability of complete wound closure versus control (RR 1.69, 95% confidence interval [CI] 1.05–2.72; I 2 = 0%). One assessor‐blinded RCT of collagen alone reported higher 12‐week closure versus a placebo dressing and was not pooled due to heterogeneity. Across studies, signals also favored collagen‐based care for earlier area reduction and, in one trial, fewer infection‐related withdrawals; mechanistic work showed reductions in MMP‐9/TIMP‐2. However, most trials were small and single‐centre, comparators and adjuncts varied, follow‐up was short (~8 days–24 weeks, clinical endpoints typically 4–20 weeks), outcome definitions were non‐standardised, and key confounders (off‐loading, infection management, vascular status, glycaemic control) were inconsistently addressed. Collagen‐based dressings—particularly collagen‐combination formulations—appear to improve complete closure when added to the standard of care (SOC) for diabetic foot ulcers (DFUs), but the evidence is limited by study size, heterogeneity, and risk of bias. Larger, prospectively registered, multicentre RCTs with standardised outcomes and longer follow‐up are needed to define clinical and cost‐effectiveness and to identify which patients benefit most. Collagen–ORC dressings show promise as an adjunctive treatment for DFUs by influencing the inflammatory microenvironment and supporting tissue repair. However, the certainty of the current evidence remains limited, highlighting the need for further high‐quality randomised studies.

26 May 2026 in Wound Repair and Regeneration
Verified
Journal Article
Closed access
George TheodorakopoulosGeorge Theodorakopoulos
George Theodorakopoulos
David ArmstrongDavid Armstrong
David Armstrong

1 October 2026 in International Wound Journal
Verified
Journal Article
Open access
George TheodorakopoulosGeorge Theodorakopoulos
George Theodorakopoulos
David ArmstrongDavid Armstrong
David Armstrong
Placental‐derived cellular, acellular, and matrix‐like products (CAMPs) are widely used as adjuncts to standard care for diabetic foot ulcers (DFUs), but trials differ in product class, comparator, and healing window. We estimated the effect of adjunctive placental‐derived CAMPs on complete wound closure at a single, clinically meaningful 12‐week endpoint. The review was registered in the International Prospective Register of Systematic Reviews (PROSPERO; CRD420261399700) and reported per Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) 2020, with search reporting guided by PRISMA‐S. PubMed/MEDLINE, Scopus, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched through 21 June 2026 for randomised or quasi‐randomised trials comparing a placental, amniotic, chorionic, amnion‐chorion, placental membrane, or umbilical cord‐derived product plus standard care against standard care or a non‐placental control in adults with active DFUs. The primary outcome was complete wound closure at 12 weeks. Risk ratios (RRs) were pooled in a random‐effects model (inverse‐variance, restricted maximum likelihood [REML], Hartung‐Knapp). Risk of bias was assessed with the Cochrane Risk of Bias 2 tool (RoB 2) for the 12‐week outcome and certainty with the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Prespecified sensitivity analyses included odds ratios, leave‐one‐out, product‐class subgroups, and exclusion of high‐risk‐of‐bias studies. Of 474 records, 14 randomised articles were retained; 9 standard‐care‐controlled comparisons (944 participants) provided extractable 12‐week complete‐closure data for the primary analysis. Complete closure occurred in 298 of 505 product‐treated participants (59.0%) versus 157 of 439 controls (35.8%). Adjunctive CAMPs increased the likelihood of closure (RR 1.70, 95% confidence interval [CI] 1.31–2.20). Heterogeneity was moderate (I 2 = 51.9%) and the prediction interval crossed the null (0.93–3.11). The effect was robust to leave‐one‐out analysis (RR 1.59–1.81), an odds‐ratio model (odds ratio [OR] 3.36, 95% CI 1.68–6.71), and exclusion of the single high‐risk‐of‐bias trial (RR 1.73, 95% CI 1.29–2.33). Certainty was moderate, downgraded once for inconsistency. Adjunctive placental‐derived CAMPs improve 12‐week complete closure of DFUs compared with standard care, with moderate certainty. The wide prediction interval indicates that the average benefit may not be reproduced by every product, population, or setting, underscoring the need for product‐specific, standard‐care‐anchored trials and for coverage policy grounded in endpoint‐specific randomised evidence. Trial Registration: Registration number: CRD420261399700.

6 July 2026 in Diabetes/Metabolism Research and Reviews
Verified
Journal Article
Open access
PJPetra Jones
Petra Jones
David ArmstrongDavid Armstrong
David Armstrong
ARAlex Rowlands
Alex Rowlands
Harald SourijHarald Sourij
Harald Sourij
ANAfsaneh Noormandi
Afsaneh Noormandi
George TheodorakopoulosGeorge Theodorakopoulos
George Theodorakopoulos
Aims: Those at risk of diabetes‐related foot ulceration (DFU) must balance sufficient physical activity to maintain glycaemic control and cardiovascular health whilst avoiding excessive trauma to their feet. Our systematic review aimed to assess whether physical inactivity and/or sedentary behaviour affect DFU outcomes. Materials and Methods: Embase, Medline, and Scopus were searched for peer‐reviewed studies using the criteria: (‘diabetes’ OR ‘diabetic’) AND (‘physical*’ OR ‘activ*’ OR ‘inactiv*’ OR ‘sedentary’) AND ‘foot’ AND ‘ulcer’, returning 4650 results excluding duplicates. 16 studies were included and assessed for risk of bias using the Newcastle‐Ottawa Scale (NOS). Results: Fifteen studies assessed physical inactivity and 1 assessed both inactivity and sedentary behaviour and DFU outcomes. Eleven of 16 (69%) studies reported significantly greater likelihood of DFU in inactive participants. Exploratory meta‐analysis suggested physical inactivity to be associated with doubled DFU risk (OR 2.09, 95% CI 1.32–3.32, p = 0.002). Evidence that sedentary behaviour was associated with tripled DFU risk was based on a single prospective cohort and had a high risk of bias (OR 2.95, 95% CI: 1.5–6.4, p = 0.008; n = 175, NOS: poor). Study methodologies were heterogenous (e.g., inconsistent definitions of inactive), with habitual physical activity measured through interviews, patient records, or questionnaires in 14 of 16 studies (NOS rating: poor to fair). Conclusions: Available evidence suggested that physical inactivity and sedentary behaviour were associated with an increased risk of DFU. Further research is needed to develop thresholds for physical inactivity and sedentary behaviour to reduce DFU risk.